Core Insights - Ipsen has announced its half-year statement regarding the liquidity agreement with NATIXIS ODDO BHF, detailing the resources allocated to the dedicated liquidity account as of June 30, 2025 [1] - The company operates as a global biopharmaceutical entity focusing on transformative medicines in oncology, rare diseases, and neuroscience, leveraging nearly 100 years of development experience [2] - Ipsen is publicly listed on Euronext in Paris and has a Sponsored Level I American Depositary Receipt program in the U.S. [3] Financial Summary - As of June 30, 2025, the liquidity account included 38,030 shares valued at €1,320,416.64 and 12,751 shares valued at €3,137,934.80 [6] - The trading volume during the period from January 1, 2025, to June 30, 2025, included 2,468 purchase transactions and 2,393 sell transactions, with a total of 339,729 shares purchased for €36,644,907.65 and 326,400 shares sold for €35,329,344.25 [6]
Ipsen - Half year statement - 2025 06 30
Globenewswire·2025-07-07 16:00